Skip Content
Page Banner Image

Pride-HD Study

Back to map

Sponsored by Teva Branded Pharmaceutical Products, R&D Inc.

Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of HD. The purpose of this randomized, double blind study is to see what effect the investigational drug, pridopidine, has on movement, thinking, and behavior, compared to placebo, in people with HD after receiving either pridopidine or placebo. In addition, information will be collected about safety and tolerability of pridopidine in people with HD.

This study is not currently recruiting participants. If you have any questions as a past participant, please connect with the clinical trial site directly.


Formal Name
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington’s Disease

Study Type

This is a multicentre, multinational, randomized, parallel-group, double-blind, placebo-controlled, does range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington disease (HD).

Canadian Locations and Contact Information

British Columbia
Teva Investigational Site 11035
Status: Not recruiting
Location: Centre for HD, UBC Hospital, Vancouver
Coordinator: Joji Decolongon
Phone: 604-875-3801

Teva Investigational Site 11036
Status: Not recruiting
Location: Centre for Movement Disorders, Toronto
Coordinator: Theresa Moore
Phone: 416-847-7084

Teva Investigational Site 11037
Status: Not recruiting
Location: The Ottawa Hospital Civic Campus, Ottawa
Coordinator: Diane Cote & Jennifer Conway
Phone: 613-562-4235

Exclusion Criteria       (individuals who do not meet inclusion criteria)

  • Patients with clinically significant heart disease at the screening visit
  • Treatment with tetrabenazine within 6 weeks of study screening
  • Patients with a history of epilepsy or of seizures within the last 5 years
  • Have other serious medical illnesses in the opinion of the investigator may put the patient at risk when participating in the study or may influence the results of the study or affect the patient’s ability to take part in the study
  • Patients receiving medications (within the last 6 weeks prior to screening) that have been proven to prolong QT interval or who may require such medications during the course of the study such as but not limited to non allowed anti psychotic medications, tricyclic antidepressants and/or Class I antiarrhythmics
  • Patients receiving medications (within the last 6 weeks prior to screening) that are metabolized by CYP2D6 and have the potential of reducing seizure threshold
  • Other criteria apply, please contact the investigator for more information

Source A service of the U.S. National Institutes of Health
Verified April 2015 by Teva Pharmaceutical Industries
Information provided by (Responsible Party):
Teva Pharmaceutical Industries (Teva Branded Pharmaceutical Products, R&D Inc. )

For more detailed information on this study and others and for the most recent updates, please go to is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. 

Back to map

Leave a Reply

You must be logged in to post a comment.

We support those facing huntington disease
 Latest Blog


Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up